Two previous studies demonstrated that YAP-induced anti-apoptosis worsens the initial treatment response to BRAF and MEK inhibitors and EGFR-TKIs in NSCLC cells with K-ras, BRAF-V600E, or EGFR mutations [89,97]. Here, MAP2K7 is linked to non-small cell lung carcinoma.